Background. Central to the pathologic progression of human cerebral malaria (CM) is sequestration of Plasmodium falciparum-infected red blood cells (Pf-IRBCs) to the blood-brain barrier (BBB) endothelium. The molecular interactions between Pf-IRBCs and the BBB endothelium and their implications for barrier function are unclear.
(BBB), activating its endothelium and leading to BBB dysfunction. The degree of BBB activation varies from small transient effects, such as increased cell adhesion molecule expression, to altered endothelial morphology and the presence of immune deposits. More-profound changes leading to BBB dysfunction include reduced expression of BBB junctional proteins and leakage of serum proteins into the central nervous system [3] [4] [5] [6] [7] . In severe cases of CM, intraendothelial accumulation of pigment and passive extravasation of Pf-IRBC, possibly through small BBB lesions, can occur [3, 8, 9] . In addition, morphological and functional changes have been observed in glia and axons [10] . The BBB endothelium is at the crucial interface between Pf-IRBCs confined to the capillary endothelium and neuronal damage in the brain. At present, it is not clearly understood how sequestered parasites induce the neurological symptoms associated with CM. A combination of parasite and host-specific factors, such as the release of bioactive molecules and impaired oxygen delivery, may contribute [2, [11] [12] [13] . However, the underlying pathogenic mechanisms of Pf-IRBC-mediated endothelial dysfunction and neuronal damage in CM remain enigmatic.
We hypothesized that adherent Pf-IRBCs impair the integrity of the BBB, followed by an influx of soluble parasite and/or host plasma factors that activate neuroglia, leading to neurotoxicity. As a model for the human BBB, we used isolated human brain microvascular endothelial cells (HBMECs) that have been extensively characterized and used in studies with various neuropathogens [14] [15] [16] [17] [18] . We focused on the effects of Pf-IRBCs on the integrity of the BBB as measured by electrical resistance, using a real-time electrical cell substrate impedance sensing (ECIS) apparatus [19] and a Transwell (TW) in vitro model of the human BBB.
MATERIALS AND METHODS
Isolation, characterization, and culture of HBMECs. Microvascular endothelial cells (ECs) were isolated from human brain specimens and characterized as described elsewhere [15, 20, 21] . In vitro models of the BBB were constructed by growing HBMECs on microporous membranes (0.4-mm pore size) in the upper compartment (for comparison with the blood side) of semipermeable TW tissue-culture inserts (24 wells; Corning). The bottom compartment was for comparison with the brain side. Transmission electron microscopy revealed a smooth EC monolayer, typical rod-shaped Weibel-Palade bodies, and tight junctions [16] . Polarity was shown after tumor necrosis factora treatment, resulting in an apical intercellular adhesion molecule (ICAM)-1 expression. Immunostaining and Western blotting showed junctional proteins zonal occludens protein-1 (ZO-1), b-catenin, and occludin-1, indicating that the HBMECs possess both endothelial and brain characteristics and functions.
Assessment of barrier integrity of HBMEC monolayers. The barrier function and integrity of the HBMEC monolayers was measured using 2 different methods. The first method used was transendothelial electrical resistance (TEER) across HBMEC monolayers in a TW-BBB model using an EndOhm chamber coupled with an endothelial voltmeter (EVOM; World Precision Instruments). Once stable measurements had been obtained from confluent HBMECs (1120 Q), Pf-IRBCs or red blood cells (RBCs) were added to the upper compartment. TEER was measured at the indicated times. The background TEER of the filter alone (∼18 Q) was subtracted. Data were calculated as percentage of control, and the change in TEER was plotted. For comparison, the TEER of macrovascular human umbilical vein EC monolayers was !30 Q.
Next, TEER measurements of HBMEC monolayers in real time were done using an ECIS apparatus (Applied Biophysics) [22] . HBMEC monolayers were grown to confluency on goldplated electrodes in 8-well array slides that attach to a computer-operated sensing apparatus, which allowed measurements in real time. At confluence, HBMEC resistance was ∼1500-1800 Q. [23] , and treatments were done as described elsewhere [21] . Briefly, sorbitol-synchronized trophozoite-stage Pf-IRBCs were purified by Percoll density-gradient centrifugation (190% parasitemia) [24, 25] . Ring-stage Pf-IRBCs were at !20 h of the life cycle, before the appearance of microscopic hemozoin indicative of the trophozoite stage. The schizont stage commences with visible nuclear division. To enrich ring-stage parasites (175% purity), Percoll-purified mature stages were incubated overnight with equal numbers of uninfected RBCs and were treated with sorbitol to remove the remainder of mature stages. To inactivate parasites inside Pf-IRBCs but to leave extracellular structures intact, Percoll-purified parasite cultures were incubated with artemisinin (1 mmol/L for 4 h) and washed twice with RPMI 1640 before they were added to HBMECs. Protein transport in Pf-IRBCs was blocked with 5 mmol/L brefeldin A (BFA; Sigma) for 4 h [26] [27] [28] .
Percoll-purified Pf-IRBCs were subfractionated using a modification of the method of Artavanis-Tsakonas and Riley [29] , as described elsewhere [21] . Briefly, Pf-IRBCs (clone 3D7 at the trophozoite stage) were lysed by 3 quick freeze-thaw cycles on dry ice and centrifuged (at 18,000 g for 10 min at 4ЊC). Supernatant was passed through a 0.2-mm filter. The pellet fraction was washed twice in RPMI 1640 and resuspended into RPMI 1640-fetal bovine serum (FBS). Microscopic characterization showed erythrocyte membrane fragments and hemozoin residual bodies. Western blotting showed parasite aldolase in the soluble fraction and erythrocyte membrane band-3 protein in the membrane fraction (data not shown).
Extracellular Pf-IRBC proteins were removed with trypsin using the method of Gardner et al. [30] with minor modifications. Briefly, Pf-IRBCs were washed with calcium-free Hanks' balanced salt solution and incubated in RPMI 1640 with 1 mg/mL trypsin (10% final hematocrit, for 3 min at room temperature). Incubation was terminated by the addition of FBS (containing trypsin inhibitors), and cells were washed with RPMI 1640-FBS. Trypsin treatment of Pf-IRBCs (for 1 h, followed by vigorous washing, fixing with 1.25% glutaraldehyde, Giemsa staining, and counting) effectively reduced adhesion to HBMECs. An HBMEC-binding parasite line (3D7) was obtained by 3 cycles of panning on confluent HBMEC monolayers, as described elsewhere [31] , with minor modifications. Briefly, ∼1 ϫ 10 8 mature-stage parasites were added to confluent HBMEC monolayers and incubated (for 1 h at 37ЊC) in RPMI 1640 (pH 6.8) under gentle agitation every 15 min. Unbound Pf-IRBCs were removed, and adherent Pf-IRBCs were cultured overnight. Newly formed ring stages were amplified for 4-5 cycles before the next panning.
Collection of Pf-IRBC culture supernatants. Synchronized and purified Pf-IRBCs in the early trophozoite stage were transferred to serum-free RPMI 1640 at 50% hematocrit. Supernatant was collected 3 times for 4 h and 1 period of 12 h (overnight) until the schizont stage and were frozen at Ϫ70ЊC.
Fractionation of soluble Pf-IRBC components. Pf-IRBC culture supernatant with ∼10% parasitemia was obtained after 1 cycle of schizogony and filter sterilized (0.2 mm), and protein fractions were precipitated using ammonium sulfate (AS). The 20%, 40%, 60%, and 80% AS fractions were solubilized in 5 mL of cold PBS that contained protease inhibitors (PBS-PI; Sigma) and dialyzed overnight at 4ЊC against a 1000ϫ volume of PBS-PI. The protein content was determined using the Bradford method. Aliquots were kept at Ϫ80 ЊC.
Mycoplasma testing. Parasite isolates and ECs were tested for Mycoplasma contamination using a polymerase chain reaction-based mycoplasma detection kit (Vector) in accordance with the manufacturer's recommendations; results were found to be negative.
RESULTS

Pf-IRBC and HBMEC resistance decrease.
To assess the effect of Pf-IRBCs on BBB endothelial integrity, Percoll-purified PfIRBCs ( , , and ), at the early trophozoite creased slightly with higher numbers of RBCs and at longer incubation times.
These ECIS observations were replicated using point measurements of electrical resistance in the in vitro TW-BBB model. Again, trophozoite stages of Pf-IRBCs ( ) produced a 7 5 ϫ 10 sharp decrease in HBMEC resistance at 4.5 h, and a partial repair of the HBMEC monolayer integrity was observed at 21 h ( figure 1C) . Morphologically, the decrease in resistance was linked to disruption of cell-cell junctions as observed by immunostaining of HBMEC monolayers incubated with Pf-IRBCs and anti-ZO-1 antibody but not with uninfected RBCs (data not shown). Because Pf-IRBCs mature and lyse inside the vessels, we tested whether lysed Pf-IRBCs could affect HBMEC resistance. Lysed Pf-IRBCs, but not lysed RBCs, decreased HBMEC resistance, followed by a partial repair, ruling out host factors (e.g., hemoglobin). During Pf-IRBC maturation, an accumulation of lactate leads to acidification [32] , but adding lactate up to pH 4 did not affect HBMEC resistance (data not shown).
Two separate methods (ECIS and the TW system) for assessing barrier integrity showed a Pf-IRBC-mediated dose-and time-dependent decrease in the integrity of the BBB endothelium. Factors specific to the parasite but not related to host RBCs appeared to be responsible for the decreased HBMEC resistance. Because point measurements of HBMEC resistance using TW-BBB models are very time consuming, we chose to further determine the effects of Pf-IRBC on BBB integrity using the ECIS system, which allows direct and sensitive measurements in real time.
Stage and strain dependency. Pf-IRBCs at more mature stages have increased expression of extracellular proteins (e.g., Role of Pf-IRBC membrane versus soluble factors. To assess the possible involvement of soluble Pf-IRBC factor(s), PfIRBCs were fractionated into a pellet fraction and a supernatant fraction ( figure 4A ). The pellet/membrane fraction induced an immediate decrease in HBMEC resistance followed by a restoration and subsequent increase. This effect could not be attributed to the presence of hemozoin, because concentrations up to 40 mmol/L hemozoin and up to 100 mmol/L b-hematin did not decrease HBMEC resistance (data not shown). The supernatant fraction, which contained soluble host-erythrocyte and parasite factors, immediately and persistently decreased resistance. These data show that both soluble and membraneassociated Pf-IRBC components induce a partial decrease in HBMEC resistance but that they have different kinetics.
Role of parasite viability. Because the intraerythrocytic Plasmodium may secrete factors into the RBC cytosol, we tested whether interference with its viability and, thus, with the secretion of soluble parasite factors would affect the decrease in HBMEC resistance. Inactivation of intraerythrocytic parasites with artemisinin at ∼100 times the IC 50 ure 4B). This treatment leaves the surface structure of Pf-IRBCs intact, which suggests that, in addition to membrane components, parasite-specific soluble factors released from Pf-IRBCs mediate the decrease in HBMEC resistance.
Reduction by BFA in resistance decrease. To support the soluble factors released from Pf-IRBCs before lysis, culture supernatants from highly synchronized Pf-IRBCs at the early trophozoite stage were collected and were found to induce a decrease in HBMEC resistance (figure 5A). The magnitude of this decrease was comparable between supernatant fractions harvested at either 0-4-or 0-12-h intervals. Protein secretion of Pf-IRBCs at young trophozoite stages was blocked with BFA [26, 28] . BFA effectively reduced the magnitude of the decrease in HBMEC resistance (figure 5B). BFA-treated Pf-IRBCs developed to full schizogony and displayed a binding pattern comparable to that of nontreated Pf-IRBC ( figure 5C ). Thus, at the mature parasite trophozoite to schizont stages and before rupture, BFA-sensitive soluble components are released from Pf-IRBCs that affect HBMEC resistance.
AS precipitation of soluble Pf-IRBC components. In an initial effort to further characterize the factors released by PfIRBCs that decrease HBMEC resistance, filtered Pf-IRBC culture supernatant was subjected to AS treatment. The 40% AS fraction retained a potent ability to decrease HBMEC resistance (figure 6). The 60% AS fraction contained partial activity, but other AS fractions and corresponding fractions from RBC culture supernatant did not decrease HBMEC resistance (data not shown). This implies that the malaria parasite releases a soluble factor that can be retrieved by AS precipitation and is possibly a protein.
DISCUSSION
Here, we report the effect of Pf-IRBCs on the integrity of the host BBB endothelium using electrical resistance measurements in a TW-BBB and ECIS system. In both systems, a dose-and time-dependent decrease in electrical resistance was observed with Pf-IRBCs but not with noninfected RBCs. A threshold concentration effect (approximate cell ratio, 110) appears to exist for the TEER changes to occur, although HBMEC activation leading to ICAM-1 expression can occur at lower concentrations [21] . Parasites inside the erythrocyte mature and eventually lead to erythrocyte lysis. Similarly to whole Pf-IRBCs and RBCs, lysed infected Pf-IRBCs, but not lysed noninfected RBCs, decreased HBMEC resistance, indicating a specific parasite-mediated and not host-mediated perturbation of the monolayer barrier function. Host factors such as hemoglobin can affect the permeability of lung endothelium [34] . Lactate levels are also increased in malaria plasma and could also affect the BBB [32] . However, because we showed that lysed noninfected erythrocytes and artificial acidification do not affect HBMEC integrity, it suggests that neither hemoglobin nor lactate contributes to BBB dysfunction in CM.
It is generally believed that Pf-IRBC surface structures such as "knobs" and associated proteins (e.g., PfEMP-1) that increase during parasite maturation mediate cytoadherence [35, 36] and trigger host cell responses. That is in accordance with the finding that the HBMEC resistance-decreasing effect of Pf-IRBCs was observed in the trophozoite-schizont stages but not in the ring stages of the parasite. However, removal of extracellular Pf-IRBC proteins with trypsin resulted in reduced Pf-IRBC-HBMEC adhesion but did not affect decreases in HBMEC resistance. Subfractionation of Pf-IRBCs confirmed the partial contribution of Pf-IRBC membrane fragments. Although malaria pigments contained in the pellet-fraction can activate both human umbilical vein ECs and HBMECs, leading to ICAM-1 expression and interleukin-6 production [8, 21] , we found that hemozoin and b-hematin do not contribute to the decrease in resistance. The involvement of Pf-IRBC surface components was also confirmed by artemisinin treatment, which inactivates the intraerythrocytic parasite but leaves the Pf-IRBC surface structure intact. However, various Pf-IRBC clones (HBMECselected and ICAM-1) displaying strong HBMEC-binding profiles decreased resistance at a magnitude similar to that of the low-binding 3D7 clone. Signaling through ICAM-1 can affect junctional molecules and barrier integrity [37] . Because ICAM-1 is present on HBMECs and increases upon Pf-IRBC exposure [21] , incubation with ITG-ICAM-1 Pf-IRBCs was expected to increase the HBMEC response; surprisingly, it did not. Interfering with ICAM-1 expression on HBMECs through NF-kB with Bay11-7082, MG132, or pyrrolidine dithiocarbamate [21] also did not affect the Pf-IRBC-mediated decrease in HBMEC resistance (data not shown). Although this is remarkable, our data suggest that PfEMP-1 binding to ICAM-1 and other known and trypsin-sensitive binding determinants, such as CSA, are not involved in the HBMEC resistance-decreasing response of Pf-IRBCs. This led us to believe that other Pf-IRBC components, such as trypsin-resistant membrane components or soluble parasite factors, contributed to the resistance-decreasing effect. After subfractionation, the supernatant fraction containing soluble parasite factors clearly induced a sustained decrease in HBMEC electrical resistance. Although the magnitude of the decrease in resistance by both the soluble and membrane fraction was less than that of the total Pf-IRBCs, it appeared to be complementary, which is suggestive of synergistic effects of physical membrane interactions and soluble Pf-IRBC factors. Inactivation of intraerythrocytic parasites by artemisinin arrested the further release of soluble factors and reduced the magnitude of the decrease in HBMEC resistance. We speculated that the portion of this effect that could not be attributed to membraneassociated components was due to soluble parasite-derived factors that can be released from Pf-IRBCs. This is in agreement with the observation that filtered Pf-IRBC culture supernatants from both fully matured (ruptured) and trophozoite (nonruptured) Pf-IRBCs decreased HBMEC resistance. Thus, soluble parasite factors that affect the integrity of the BBB are released from intact Pf-IRBCs and not exclusively upon lysis.
The nature of the soluble factors and the mechanism(s) whereby these factors are released from infected erythrocytes are unclear. The present data show that the released soluble factor is precipitable with AS, which is suggestive of a protein nature. These factors/proteins could be diffusing out of the PfIRBCs or be actively released by a mechanism installed by the parasite that is unknown at present. Because the membrane properties of the Pf-IRBCs are drastically altered by the infection, smaller factors could diffuse across the erythrocyte membrane. Pf-IRBC membranes display increased rigidity, reduced deformability [38] [39] [40] , and alterations in phospholipid organization, peroxidation, and cholesterol content [41] . Pf-IRBC membranes display increased permeability to various solutes [42, 43] , and proteomic analysis of Pf-IRBCs has revealed a secretory compartment for Plasmodium proteins [44] . Both membrane-associated and soluble Plasmodium proteins, including proteins in Maurer clefts, can be delivered to the host erythrocyte cell surface [44] . In addition, the Plasmodium parasite is capable of delivering proteins outside the parasitophorous vacuole to the erythrocyte membrane [45] and of secretion of Plasmodium proteins to the cytosol [46] . In agreement with our findings, Ghigo et al. [47] showed that a soluble factor (1100 kDa) is released from Pf-IRBCs that activates human umbilical vein ECs. Moreover, serum from patients with malaria, but not from healthy donors, caused increased substance P expression on human ECs [48] , which also suggests the involvement of soluble Plasmodium factors. Our data obtained with BFA also suggest the existence of a secretory compartment involved in release of soluble Pf-IRBC factors that affect the pathogenesis of malaria. During parasite development, several proteins, including virulence and pathogenic factors, are exported from the parasite into the erythrocyte cytosol via the parasite's secretory pathway [45] . The soluble Pf-IRBC factor could involve parasite pathways analogous to the compartment shown by Wiser et al. in P. berghei [49] . Taken together, the obtained data and discussed literature illustrate that Pf-IRBC can secrete factors that activate human brain ECs. The soluble factor(s) responsible for the observed decrease in resistance may be proteins. At this point in our studies, we cannot exclude that the HBMEC resistance-decreasing factor is a membrane protein and that its release is affected by a BFA-sensitive protease. Alternatively, BFA treatment could affect a hypothetical chaperone protein of this factor. At present, we are attempting to identify the nature of the factor(s) involved in the decrease in HBMEC resistance.
Taken together and extrapolating our results, we envision that, during CM, Pf-IRBCs are sequestered in high endothelial venules through well-described interactions, such as that with PfEMP-1. These primary and close interactions may lead to the recruitment of additional and different Pf-IRBC surface molecules that activate the BBB endothelium. Concomitantly, Pf-IRBCs secrete parasite-specific proteins and toxins that could reach high local concentrations that affect the BBB. The rupture of sequestered Pf-IRBCs after schizogony would release additional parasitic factors that further affect BBB function. The combination of those factors leads to a breach in BBB integrity and allow the entry of "toxic" substances into the brain parenchyma, activating the neuropil and causing neurodysfunction. Upon maturation of all sequestered Pf-IRBCs and clearance of the venules, the soluble antigens are washed away with circulation and/or cleared by immune cells, which allows a restoration of BBB function. This would explain the reversible nature of the pathogenesis of CM and suggests the importance of parasite-driven soluble factors released from adhered PfIRBCs or released after schizogony in the induction of inflammatory responses. This scenario may contribute to the pathogenesis of CM and more specifically to pathologic changes in the BBB. In addition to Pf-IRBC-mediated barrier dysfunction, Pf-IRBC-mediated activation of immune cells leads to barrier dysfunction [50] . In vivo, these effects may either be compounded or occur consecutively, resulting in a negative impact on the pathogenesis of CM.
In conclusion, we have presented direct evidence of perturbation of BBB integrity by Pf-IRBCs through a multifactorial and multistep process. Our data support that, in addition to adherence of Pf-IRBCs to brain endothelium, trypsin-resistant membrane-associated Pf-IRBC components and parasite-specific soluble factors may play important roles in affecting the BBB integrity in the pathogenesis of CM.
